MG

Markus Goebel

Director at OSE Immunotherapeutics

Einsiedeln, Schwyz

Overview 

Markus Goebel is a highly accomplished professional with a background in the pharmaceutical industry, venture capital, and biotechnology. Currently serving as the Managing Director at Novartis Venture Fund, he has also held key roles at Novartis and Roche, with notable achievements including leading corporate M&A activities and forming strategic alliances with companies like Amgen. Additionally, Markus has made impactful investments in companies like Merganser Biotech and Sorbent Therapeutics, showcasing his expertise in the bioTech sector.

Work Experience 

OI

OSE Immunotherapeutics

  • Director

    2024 - Current

    OSE Immunotherapeutics is an integrated biotechnology company dedicated to developing First-In-Class Immunotherapies in Immuno-Inflammation (I&I) and Immuno-Oncology (I-O).

I

Innosuisse

  • Expert

    2022

hA

hemotune AG

  • Director

    2022

    hemotune AG is a pioneering Swiss biotech company based on nanoengineered magnetic beads and its breakthrough technology platform with multiple application possibilities. It has recently closed a CHF 14m Series B to advance the lead program into the clinic.

M&G Advisors GmbH

  • Founder & CEO

    2019

    Biotech and MedTech consulting

HT

HAYA Therapeutics SA

  • Director

    2020 - 2020

    HAYA Therapeutics is a Swiss-based pre-clinical early stage biopharmaceutical company dedicated to treating fibrotic diseases through the discovery and development of innovative targeted first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs.

Novartis Venture Fund

  • Managing Director

    2004 - 2019

    • Managing Director Novartis Venture Fund (NVF) 2004-2019 (US & EU) • Investments: Sirtris (sirtuins), FoldRx (protein misfolding), Locus (in-silico drug design), Trellis (human MAbs), LigoCyte (vaccines), Visiogen (IOL device; co-lead), Ra Pharma (cyclic peptides), Sorbent (polymer for CHF), Intellikine (PI3K/mTOR pathway), Avila (covalent sm; co-lead), eFFECTOR (protein translation), merganser (hepcidin mimetics), AlloCyte (LFA-1 inhibitors), Expansion (repeat mRNA; co-lead), Ribon (monoPARPs) • Key investment contributions: Ablation Frontiers (AF device), Proteostasis (protein networks), Sonitus (hearing device) • Exits: IPO: Sirtris, Proteostasis, Ra Pharma; M&A: FoldRx (Pfizer), Ablation Frontiers (Medtronic), Visiogen (Abbott), Intellikine (Takeda), Avila (Celgene), LigoCyte (Takeda)

N

Novartis

  • Head Pharma Corporate M&A

    2002 - 2004

    Acquisitions and divestments in and out of Novartis AG

  • Head Nervous System BD&L Pharma

    2000 - 2002

    Licensing options for Novartis Pharma in Nervous System

R

Roche

  • Several Marketing & Strategy positions incl. an alliance with Amgen

    1992 - 1999

    Head of Strategic Portfolio Management & Life Cycle Planning Pharma Senior Business Analyst Strategic Unit Pharma International Medical & Registration Manager Neupogen® (in co-operation with AMGEN)

Roche Molecular Systems, Inc., a molecular diagnostics company, develops and commercializes diagnostic and blood screening tests based on

diagnostics.roche.com

FARMITALIA CARLO ERBA LIMITED

  • Medical Manager Oncology & Medical Science

    1990 - 1992

Education 

Investments 

Merganser Biotech

Series A

Total funding: $28M

Sorbent Therapeutics

Series B

Total funding: $86M

Articles About Markus

Relevant Websites